Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA2 | P42262 | 11/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 3/20 | 0.36 |
| ▸ | CA2 | P00918 | 3/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA4 | P22748 | 2/20 | 0.36 |
| ▸ | CA7 | P43166 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | SCN4A | P35499 | 1/20 | 0.36 |
| ▸ | VEGFA | P15692 | 1/20 | 0.35 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.34 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.34 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1980510 | 0.90 | VEGFA (0.45) | GRIA2CA1CA2CA12CA4 | |
| SCHEMBL1979031 | 0.88 | GRIA2 (0.41) | GRIA2VEGFA | |
| SCHEMBL1967915 | 0.87 | GRIA2 (0.53) | GRIA2 | |
| SCHEMBL1971790 | 0.86 | GRIA2 (0.40) | GRIA2CA1CA2CA12CA4 | |
| SCHEMBL1970203 | 0.86 | GRIA2 (0.40) | GRIA2ALDH1A1ABCC8KCNJ11 | |
| Hydrochloric Acid SCHEMBL2811105 | 0.85 | GRIA2 (0.40) | GRIA2ALDH1A1 | |
| SCHEMBL1982798 | 0.82 | ADAM17 (0.46) | GRIA2ALDH1A1ABCC8KCNJ11 | |
| SCHEMBL1978280 | 0.80 | GRIA2 (0.44) | GRIA2 | |
| SCHEMBL1981334 | 0.80 | CA2 (0.54) | GRIA2ALDH1A1CA1CA2CA12 | |
| SCHEMBL3761028 | 0.78 | GRIA2 (0.40) | GRIA2CA1CA2CA12CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8236790-B2 | Benzothiadiazepine compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATORIES SERVIER (FR) | 2012-08-07 | — | — | US | disclosed |
| EP-2246339-B1 | Derivatives of benzothiazepine and their use as modulators of AMPA and NMDA receptors | SERVIER LAB (FR) | 2011-06-22 | — | — | EP | disclosed |
| EP-2246339-A1 | Derivatives of benzothiazepine and their use as modulators of AMPA and NMDA receptors | Les Laboratoires Servier (FR) | 2010-11-03 | — | — | EP | disclosed |
| WO-2010106249-A1 | BENZOTHIADIAZEPINE DERIVATIVES USED AS AMPA AND NMDA RECEPTOR MODULATORS | LES LABORATOIRES SERVIER (FR) | 2010-09-23 | — | — | WO | disclosed |
| US-20100240635-A1 | Benzothiadiazepine compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240635-A1 | Benzothiadiazepine compounds, a process for their preparation and pharmaceutical compositions containing them | GRIN1, GRIN2B, GRIN3A | GRIA2 45/4885USP2 3066/4885ALDH1A1 2046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.